Phibro Animal Health Corporation Class A
PAHCPhibro Animal Health Corporation Class A (PAHC) is a global provider of innovative solutions, including vaccines, medicines, mineral feed additives, and other products aimed at improving the health and performance of animals. Founded in 1946, the company serves the livestock, poultry, and aquaculture industries with a focus on sustainability and advancing animal well-being through a broad portfolio of pharmaceutical and nutritional products.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 24, 2026 | $0.12 | 2026-06-03 | 2026-06-03 |
| March 25, 2026 | $0.12 | 2026-03-04 | 2026-03-04 |
| December 17, 2025 | $0.12 | 2025-11-26 | 2025-11-26 |
| September 24, 2025 | $0.12 | 2025-09-03 | 2025-09-03 |
| June 25, 2025 | $0.12 | 2025-06-04 | 2025-06-04 |
Dividends Summary
- Consistent Payer: Phibro Animal Health Corporation Class A has rewarded shareholders with 48 dividend payments over the past 12 years.
- Total Returned Value: Investors who held PAHC shares during this period received a total of $5.42 per share in dividend income.
- Latest Payout: The most recent dividend of $0.12/share was paid 24 days ago, on June 24, 2026.
- Yield & Schedule: PAHC currently pays dividends quarterly with an annual yield of 1.44%.
- Dividend Growth: Since 2014, the dividend payout has grown by 20.0%, from $0.10 to $0.12.
- Dividend Reliability: PAHC has maintained or increased its dividend for 48 consecutive payments.
Company News
Jack Bendheim, CEO of Phibro Animal Health Corporation, sold 18,608 shares worth $1 million through a pre-scheduled trading plan adopted in December 2025, coinciding with his transition to Executive Chairman as his son Daniel takes over as CEO on July 1, 2026. Despite the sale reducing his indirect holdings by about 25%, Bendheim maintains signif...
Jack Bendheim, President and CEO of Phibro Animal Health Corporation, sold 72,198 shares indirectly for approximately $3.74 million between February 10-11, 2026, under a pre-existing Rule 10b5-1 trading plan. The sale occurred following strong Q2 2026 earnings with year-over-year growth in revenue, net income, and EPS. The company's medicated fee...
The global glycolic acid market is projected to grow at a CAGR of 5.73% from 2026 to 2032, reaching USD 461.74 Million by 2032, up from USD 295.68 Million in 2024. Growth is driven by increasing demand in personal care, pharmaceuticals, and industrial cleaning applications, though regulatory challenges and raw material price volatility pose restr...
Phibro Animal Health reported strong Q4 FY2025 earnings, with 39% revenue growth driven by the Zoetis medicated feed additive acquisition. Despite robust sales and adjusted EBITDA, gross margins declined due to higher distribution costs and product mix challenges.
The article recommends two value stocks to buy for February 14th: Adtalem Global Education (ATGE) and Phibro Animal Health (PAHC). Both companies have a Zacks Rank #1 and have seen their earnings estimates increase in the last 60 days, indicating positive sentiment.
